论文部分内容阅读
目的:探讨和分析氨溴索+人免疫球蛋白静脉滴注治疗小儿重症肺炎的效果。方法:选取2013年11月至2016年11月期间在本院接受临床治疗的60例重症肺炎患儿作为研究对象,按照随机数字法分为两组,每组分别有30例患儿,对对照组患儿进行常规抗感染治疗,对实验组患儿进行常规抗感染治疗的基础上增加氨溴索+人免疫球蛋白静脉滴注治疗,分析两组患儿的效果。结果:实验组患儿的临床治疗总有效率(93.33%)与对照组患儿(66.67%)相比较,组间差异明显(P<0.05);实验组患儿家长的治疗满意度(96.67%)与对照组患儿家长(70.00%)相比较,组间差异明显(P<0.05)。结论:应用氨溴索+人免疫球蛋白治疗小儿重症肺炎的效果较好。
Objective: To investigate and analyze the effect of intravenous infusion of ambroxol + human immunoglobulin in children with severe pneumonia. Methods: Sixty children with severe pneumonia undergoing clinical treatment in our hospital from November 2013 to November 2016 were selected as subjects and divided into two groups according to random number method: 30 children in each group, The patients were treated with routine anti-infective therapy. Ambroxol + human immunoglobulin was intravenously injected on the basis of routine anti-infective treatment in children in experimental group, and the effect of two groups of children was analyzed. Results: The total effective rate (93.33%) in the experimental group was significantly higher than that in the control group (66.67%) (P <0.05). The treatment satisfaction of the parents in the experimental group was 96.67% ) Was significantly higher than that of the control group (70.00%) (P <0.05). Conclusion: The application of ambroxol + human immunoglobulin in children with severe pneumonia is better.